GlobalData on MSN
Virta Health reports improved outcomes in pancreatic cancer trial
The trial enrolled patients who received a triplet chemotherapy regimen of nab-paclitaxel, cisplatin, and gemcitabine.
Results from ROSELLA showed a 35% reduction in the risk of death in patients treated with relacorilant plus nab-paclitaxel compared with nab-paclitaxel alone. Treatment with relacorilant, an ...
CHICAGO -- Combining investigational relacorilant with nab-paclitaxel (Abraxane) improved progression-free survival (PFS), and demonstrated a clinically meaningful trend towards an overall survival ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...
Relacorilant plus nab-paclitaxel chemotherapy reduced the risk of disease progression by 30% compared with nab-paclitaxel alone. Treatment with relacorilant plus nab-paclitaxel improved progression ...
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study The GeparSepto trial ...
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database A safety cohort ...
SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results